Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy With Cisplatin

• Published in: Anticancer research Vol. 41; no. 3; pp. 1641 - 1646
• Main Authors: Chen, Kerry L, Shamavonian, Raphael, Karpes, Josh B, Alzahrani, Nayef A, Morris, David L
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.03.2021
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - epidemiology; Adult; Chemotherapy; Cisplatin; Cisplatin - adverse effects; Diuresis; Female; Health risks; Humans; Hyperthermic Intraperitoneal Chemotherapy - adverse effects; Incidence; Kidneys; Male; Middle Aged; Peritoneum; Retrospective Studies; Risk analysis; Risk factors; Surgery; acute kidney injury; hyperthermic intraperitoneal chemotherapy; cisplatin; incidence; peritoneal carcinomatosis; Clinical study
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.14926

Cisplatin increases the risk of acute kidney injury (AKI) during systemic chemotherapy. However, little is known about its risk of inducing AKI when used during intraperitoneal chemotherapy. This study aimed to determine the incidence of AKI in patients undergoing cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) with cisplatin. A retrospective analysis of patients who received cisplatin-based HIPEC from November 2008 to March 2018 was undertaken to determine the incidence of AKI. A total of 111 patients were identified. The incidence of AKI was 15.3% (17/111). Univariate analysis showed increased peritoneal cancer index (PCI), low intraoperative and post-operative urine output were significantly associated with the development of AKI. Multivariate analyses did not identify any significant predictors factors for AKI. Cisplatin-based HIPEC is associated with AKI. At our centre, the incidence of AKI was 15.3%. Risk factors that may influence its development include high PCI and low perioperative diuresis.